Gianquinto, E.; Sodano, F.; Rolando, B.; Kostrzewa, M.; Allarà , M.; Mahmoud, A.M.; Kumar, P.; Spyrakis, F.; Ligresti, A.; Chegaev, K.
N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation. Molecules 2022, 27, 8152.
https://doi.org/10.3390/molecules27238152
AMA Style
Gianquinto E, Sodano F, Rolando B, Kostrzewa M, Allarà M, Mahmoud AM, Kumar P, Spyrakis F, Ligresti A, Chegaev K.
N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation. Molecules. 2022; 27(23):8152.
https://doi.org/10.3390/molecules27238152
Chicago/Turabian Style
Gianquinto, Eleonora, Federica Sodano, Barbara Rolando, Magdalena Kostrzewa, Marco Allarà , Ali Mokhtar Mahmoud, Poulami Kumar, Francesca Spyrakis, Alessia Ligresti, and Konstantin Chegaev.
2022. "N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation" Molecules 27, no. 23: 8152.
https://doi.org/10.3390/molecules27238152
APA Style
Gianquinto, E., Sodano, F., Rolando, B., Kostrzewa, M., Allarà , M., Mahmoud, A. M., Kumar, P., Spyrakis, F., Ligresti, A., & Chegaev, K.
(2022). N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation. Molecules, 27(23), 8152.
https://doi.org/10.3390/molecules27238152